BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29571273)

  • 41. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
    Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
    J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
    McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
    Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
    Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
    Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries.
    Hoefeler H; Duran I; Hechmati G; Garzon Rodriguez C; Lüftner D; Ashcroft J; Bahl A; Atchison C; Wei R; Thomas E; Lorusso V
    J Bone Oncol; 2014 May; 3(2):40-8. PubMed ID: 26909296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Burden of venous leg ulcers in the United States.
    Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
    J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic burden of osteoporotic fractures in US managed care enrollees.
    Williams SA; Chastek B; Sundquist K; Barrera-Sierra S; Leader D; Weiss RJ; Wang Y; Curtis JR
    Am J Manag Care; 2020 May; 26(5):e142-e149. PubMed ID: 32436682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
    Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
    Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
    Hagiwara M; Panjabi S; Sharma A; Delea TE
    J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
    [No Abstract]   [Full Text] [Related]  

  • 51. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 52. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
    Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
    Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
    Broder MS; Cai B; Chang E; Yan T; Benson AB
    J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
    Zhou Z; Fan Y; Tang W; Liu X; Thomason D; Zhou ZY; Macaulay D; Fischer A
    J Rheumatol; 2019 Aug; 46(8):920-927. PubMed ID: 30770505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 59. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
    Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
    J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.